Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 01 Jul 2024 for GYRE THERAPEUTICS, INC., €22k. Read the official filing
Filing timeline
BuySaleNassim Usman
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
0%
Median T+90
-23.5%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +67.9%Entry 112.00 · Close at T+365 188.00
- -56.7%Entry 203.00 · Close at T+365 88.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Nassim Usman: trading record in brief
Nassim Usman (chief executive) discloses dealings in Gyre Therapeutics, Inc. to SEC (Form 4). In total, 8 filings cover trades dated from 9 August 2021 to 28 June 2024.
Every open-market trade on record is a purchase: 3 purchases worth €5,479, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 4 option exercises.
The median purchase comes to €1,496. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
The record was last updated on 1 July 2024 with an option exercise (€22k) in Gyre Therapeutics, Inc. The last purchase on record was published on 10 August 2022, which is 1,530 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Nassim Usman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
3,452 shares@ US$6.935.5% of flowCommon StockSEC:0001140361-24-032024:0
20,000 shares@ US$6.9331.7% of flowCommon StockSEC:0001140361-24-024125:0
20,000 shares@ US$6.9331.6% of flowCommon StockSEC:0001140361-24-017566:0
20,000 shares@ US$6.9331.2% of flowCommon StockSEC:0001140361-24-014164:0
24.541 sharesSeries Y Preferred StockSEC:0001140361-23-042367:0
3,250 shares@ US$0.4727.3% of flowCommon StockSEC:0001209191-22-045256:0
Canonical exit: 7 Nov 2022 (T+90)
3,250 shares@ US$0.4623.9% of flowCommon StockSEC:0001209191-22-010407:0
Canonical exit: 10 May 2022 (T+90)
867 shares@ US$3.6248.8% of flowCommon StockSEC:0001209191-21-050759:0
Canonical exit: 7 Nov 2021 (T+90)
8 of 7 declarations
